Analysts See 60% Upside for Teva Pharmaceutical Industries Stock. The Chart Disagrees

Teva Pharmaceutical Industries stock closed at $30.81 on July 24, sitting below key moving averages. Wall Street analysts project over 60% upside with a 100% buy rating. The daily chart, however, is not confirming that optimism. The gap between bullish narratives and technical weakness defines TEVA’s current tension.

Key takeaways

• TEVA closed at $30.81 on July 24, below the daily EMA20 at $32.17 and EMA50 at $32.81
• The EMA200 at $29.94 serves as the critical structural floor that must hold for any recovery
• Daily RSI at 40.15 reflects weak momentum, while the MACD confirms persistent downward pressure
• Wall Street analysts maintain a 100% buy rating with price targets implying over 60% upside
• The hourly MACD histogram shows a slight positive divergence, hinting at fading selling pressure near current levels

Daily Timeframe: Bearish Pressure Beneath the Surface

The daily chart leans bearish despite an official neutral regime reading. Price sits below both the EMA20 and EMA50, with only the EMA200 providing structural support.

… Continue reading the full article at the original source below.